Wilson Sonsini Goodrich & Rosati advised Arcellx on the deal.Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series C…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
